NCT01260402

Brief Summary

Biventricular pacing is a validated treatment for patients suffering from heart failure resistant to medical treatment. However, up to 30% of the patients are non responsive to this strategy using the coronary sinus approach to pace the Left Ventricle (LV). It has been demonstrated that the magnitude of the improvement was highly dependant on the LV pacing site. The coronary sinus approach rarely offers more than 1 or 2 potential pacing sites. Resynchronisation using a transeptal approach to pace the left ventricle on the cardiology has been shown feasible on small series. We therefore would like to compare these two approached in a randomised prospective study to confirm the hypotheses that endocardial LV pacing by offering multiple choices for the pacing sites reduces the number of non responders and is associated with greater hemodynamic benefit when compared to the conventional coronary sinus approach.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable heart-failure

Timeline
Completed

Started Mar 2011

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 8, 2010

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 15, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

March 3, 2011

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2015

Completed
Last Updated

May 14, 2026

Status Verified

February 1, 2022

Enrollment Period

3.8 years

First QC Date

December 8, 2010

Last Update Submit

May 11, 2026

Conditions

Keywords

heart failureCardiomyopathy, dilatedCoronary diseaseCardiac Pacing, Artificialcardiac resynchronization therapyHemodynamicsRandomized Controlled TrialsOpen Study

Outcome Measures

Primary Outcomes (1)

  • the acute hemodynamic response judged by dP/dt max

    The primary outcome will be the acute hemodynamic response of the randomized pacing modality (endocardial vs epicardial Left Ventricle pacing) as judged by the highest gain in dP/dt max

    Visit 3 : implantation day, during pacing procedure

Secondary Outcomes (23)

  • Implant success rate

    Visit 3 : implantation day, end of pacing procedure

  • number of left ventricular pacing sites assessed

    Visit 3 : implantation day, end of pacing procedure

  • Pacing Procedure duration

    Visit 3 : implantation day, end of pacing procedure

  • Per and post implantation complications rate

    Visit 4 : within 7 days after pacing procedure

  • Post implantation echocardiography comparing spontaneous rhythm and biventricular pacing for left ventricle ejection fraction

    within 7 days after pacing procedure

  • +18 more secondary outcomes

Study Arms (2)

Epicardial

ACTIVE COMPARATOR
Device: Resynchronization using a coronary sinus approach

Endocardial

EXPERIMENTAL
Device: Resynchronization using a transeptal approach

Interventions

Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture. Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire

Endocardial

Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus. Devices used for procedure : RADI PressureWire, routine catheters chosen by operator

Epicardial

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (aged 18 or above)
  • Cardiac insufficiency of whatever cause (ischemic or non-ischemic)
  • Left ventricular ejection fraction \<35%
  • NYHA Class III or IV with optimal medical treatment
  • QRS duration \> 120 ms
  • Sinus rhythm
  • Patient must have signed informed consent
  • Patient must be registered in the national health care system

You may not qualify if:

  • Aged under 18
  • Patient with a mitral or aortic prosthesis
  • Patient with contraindication to anti-coagulants
  • Pregnant women
  • Participation in another study
  • Patient with contraindication for left ventricle catheterization by retrograde aortic approach , as a severe aortic stenosis requiring surgery, or an ascending aorta aneurism

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiologic Hospital Haut l'évêque

Pessac, 33604, France

Location

Related Publications (1)

  • Kitamura T, Martin R, Frontera A, Jais P. Atrial tachycardia originating from deep septum following catheter ablation for persistent atrial fibrillation. Europace. 2018 Oct 1;20(10):1590. doi: 10.1093/europace/euy060. No abstract available.

MeSH Terms

Conditions

Heart FailureCardiomyopathy, DilatedCoronary Disease

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesCardiomegalyCardiomyopathiesLaminopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMyocardial IschemiaVascular Diseases

Study Officials

  • Pierre JAIS, MD

    University Hospital Bordeaux, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 8, 2010

First Posted

December 15, 2010

Study Start

March 3, 2011

Primary Completion

January 1, 2015

Study Completion

July 30, 2015

Last Updated

May 14, 2026

Record last verified: 2022-02

Locations